Tiago Fauth
Stock Analyst at Wells Fargo
(2.29)
# 2,723
Out of 5,005 analysts
158
Total ratings
42.15%
Success rate
-1.65%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $7.15 | +151.75% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $453.07 | -8.62% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $5.76 | +73.61% | 2 | Sep 3, 2025 | |
| INSM Insmed | Maintains: Overweight | $140 → $171 | $157.16 | +8.81% | 8 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $65.37 | +11.67% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $22.43 | +38.21% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $456.35 | -13.44% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $31.21 | +108.27% | 8 | Jul 10, 2025 | |
| VRNA Verona Pharma | Downgrades: Equal-Weight | $138 → $107 | $106.79 | +0.20% | 7 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $52.86 | +43.78% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $3.49 | +100.57% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $15.24 | +562.73% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.52 | +97.37% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $15.94 | +63.11% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $8.20 | +107.32% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $67.78 | +10.65% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $3.60 | +1,622.22% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $204.05 | -56.38% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $21.65 | +135.57% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $55.43 | +116.49% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $16.90 | -76.33% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $3.38 | +314.20% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $8.82 | +3,301.36% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $9.57 | +171.68% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $5.90 | +374.58% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $23.80 | +240.34% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.69 | +1,053.07% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.57 | +444.75% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $2.18 | +1,459.63% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $3.79 | +3,857.78% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $40.09 | -27.66% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.63 | +697.55% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $3.92 | +231.63% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $1.58 | +26.58% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $800.00 | -57.50% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $297.89 | -13.06% | 1 | Apr 28, 2021 |
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $7.15
Upside: +151.75%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $453.07
Upside: -8.62%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $5.76
Upside: +73.61%
Insmed
Sep 3, 2025
Maintains: Overweight
Price Target: $140 → $171
Current: $157.16
Upside: +8.81%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $65.37
Upside: +11.67%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $22.43
Upside: +38.21%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $456.35
Upside: -13.44%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $31.21
Upside: +108.27%
Verona Pharma
Jul 10, 2025
Downgrades: Equal-Weight
Price Target: $138 → $107
Current: $106.79
Upside: +0.20%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $52.86
Upside: +43.78%
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $3.49
Upside: +100.57%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $15.24
Upside: +562.73%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.52
Upside: +97.37%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $15.94
Upside: +63.11%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $8.20
Upside: +107.32%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $67.78
Upside: +10.65%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $3.60
Upside: +1,622.22%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $204.05
Upside: -56.38%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $21.65
Upside: +135.57%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $55.43
Upside: +116.49%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $16.90
Upside: -76.33%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $3.38
Upside: +314.20%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $8.82
Upside: +3,301.36%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $9.57
Upside: +171.68%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $5.90
Upside: +374.58%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $23.80
Upside: +240.34%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.69
Upside: +1,053.07%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.57
Upside: +444.75%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $2.18
Upside: +1,459.63%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $3.79
Upside: +3,857.78%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $40.09
Upside: -27.66%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.63
Upside: +697.55%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $3.92
Upside: +231.63%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.58
Upside: +26.58%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $800.00
Upside: -57.50%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $297.89
Upside: -13.06%